Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Anika Therapeutics

DB:AKP
Snowflake Description

Good value with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AKP
DB
$394M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The last earnings update was 30 days ago. More info.


Add to Portfolio Compare Print
  • Anika Therapeutics has significant price volatility in the past 3 months.
AKP Share Price and Events
7 Day Returns
3.9%
DB:AKP
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-0.6%
DB:AKP
-13.2%
DE Biotechs
-20.9%
DE Market
AKP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anika Therapeutics (AKP) 3.9% -29.1% -44.9% -0.6% -33.4% -29.5%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • AKP outperformed the Biotechs industry which returned -13.2% over the past year.
  • AKP outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
AKP
Industry
5yr Volatility vs Market

AKP Value

 Is Anika Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Anika Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Anika Therapeutics.

DB:AKP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AKP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (5.71%))
1.162
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.162 * 5.44%)
5.93%

Discounted Cash Flow Calculation for DB:AKP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Anika Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:AKP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.93%)
2020 24.08 Analyst x2 22.73
2021 35.85 Analyst x2 31.95
2022 36.73 Est @ 2.46% 30.90
2023 37.32 Est @ 1.6% 29.64
2024 37.69 Est @ 1.01% 28.26
2025 37.91 Est @ 0.59% 26.83
2026 38.02 Est @ 0.29% 25.41
2027 38.06 Est @ 0.09% 24.00
2028 38.04 Est @ -0.06% 22.65
2029 37.98 Est @ -0.16% 21.35
Present value of next 10 years cash flows $263.00
DB:AKP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $37.98 × (1 + -0.39%) ÷ (5.93% – -0.39%)
$598.57
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $598.57 ÷ (1 + 5.93%)10
$336.45
DB:AKP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $263.00 + $336.45
$599.45
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $599.45 / 14.17
$42.31
DB:AKP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AKP represents 0.96299x of NasdaqGS:ANIK
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.96299x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 42.31 x 0.96299
€40.74
Value per share (EUR) From above. €40.74
Current discount Discount to share price of €26.80
= -1 x (€26.80 - €40.74) / €40.74
34.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Anika Therapeutics is available for.
Intrinsic value
34%
Share price is €26.8 vs Future cash flow value of €40.74
Current Discount Checks
For Anika Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Anika Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Anika Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anika Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anika Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AKP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $1.93
NasdaqGS:ANIK Share Price ** NasdaqGS (2020-04-03) in USD $27.83
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anika Therapeutics.

DB:AKP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ANIK Share Price ÷ EPS (both in USD)

= 27.83 ÷ 1.93

14.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anika Therapeutics is good value based on earnings compared to the Europe Biotechs industry average.
  • Anika Therapeutics is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Anika Therapeutics's expected growth come at a high price?
Raw Data
DB:AKP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 14.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
3.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

DB:AKP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 14.45x ÷ 3.8%

3.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anika Therapeutics is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Anika Therapeutics's assets?
Raw Data
DB:AKP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $20.16
NasdaqGS:ANIK Share Price * NasdaqGS (2020-04-03) in USD $27.83
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:AKP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ANIK Share Price ÷ Book Value per Share (both in USD)

= 27.83 ÷ 20.16

1.38x

* Primary Listing of Anika Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anika Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Anika Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Anika Therapeutics has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AKP Future Performance

 How is Anika Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
3.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anika Therapeutics expected to grow at an attractive rate?
  • Anika Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Anika Therapeutics's earnings growth is positive but not above the Germany market average.
  • Anika Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AKP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AKP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 3.8%
DB:AKP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 20.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AKP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AKP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 176 37 29 3
2020-12-31 162 29 7 3
2020-04-05
DB:AKP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 115 37 27
2019-09-30 112 34 31
2019-06-30 109 35 29
2019-03-31 109 34 30
2018-12-31 106 35 19
2018-09-30 108 32 19
2018-06-30 108 33 18
2018-03-31 111 35 20
2017-12-31 113 41 32
2017-09-30 113 40 32
2017-06-30 111 39 34
2017-03-31 104 32 31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Anika Therapeutics's earnings are expected to grow by 3.8% yearly, however this is not considered high growth (20% yearly).
  • Anika Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AKP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Anika Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AKP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 1.97 2.16 1.85 3.00
2020-12-31 0.49 0.59 0.41 3.00
2020-04-05
DB:AKP Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 1.93
2019-09-30 2.19
2019-06-30 2.07
2019-03-31 2.09
2018-12-31 1.30
2018-09-30 1.31
2018-06-30 1.26
2018-03-31 1.34
2017-12-31 2.18
2017-09-30 2.19
2017-06-30 2.32
2017-03-31 2.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Anika Therapeutics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Anika Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anika Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AKP Past Performance

  How has Anika Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anika Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Anika Therapeutics's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Anika Therapeutics's 1-year earnings growth exceeds its 5-year average (45.2% vs -5.2%)
  • Anika Therapeutics's earnings growth has exceeded the Europe Biotechs industry average in the past year (45.2% vs 16.1%).
Earnings and Revenue History
Anika Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anika Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AKP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 114.61 27.19 31.70 16.67
2019-09-30 111.79 30.86 30.34 16.65
2019-06-30 108.88 29.26 26.72 16.72
2019-03-31 109.01 29.92 25.64 17.29
2018-12-31 105.56 18.72 28.14 18.19
2018-09-30 107.99 19.07 26.89 18.39
2018-06-30 108.38 18.36 27.81 20.00
2018-03-31 111.30 19.64 26.36 19.72
2017-12-31 113.42 31.82 21.54 18.79
2017-09-30 112.76 31.83 20.35 17.48
2017-06-30 111.36 33.90 19.81 14.46
2017-03-31 104.48 31.15 19.09 12.80
2016-12-31 103.38 32.55 18.01 10.73
2016-09-30 105.55 35.51 17.05 10.09
2016-06-30 103.44 34.93 16.08 9.33
2016-03-31 99.76 34.14 15.21 8.35
2015-12-31 93.00 30.76 14.83 8.29
2015-09-30 85.36 27.53 13.97 7.95
2015-06-30 83.73 25.32 14.71 7.89
2015-03-31 87.10 26.80 15.19 7.95
2014-12-31 105.60 38.32 15.07 8.14
2014-09-30 103.59 37.16 13.80 8.19
2014-06-30 99.29 35.94 12.95 7.81
2014-03-31 93.84 32.54 12.48 7.76
2013-12-31 75.08 20.58 12.94 7.06
2013-09-30 76.44 18.38 14.20 6.37
2013-06-30 73.45 15.07 14.62 5.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Anika Therapeutics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Anika Therapeutics used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Anika Therapeutics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Anika Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anika Therapeutics has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AKP Health

 How is Anika Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anika Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Anika Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anika Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Anika Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are -6.5951275893167E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anika Therapeutics Company Filings, last reported 3 months ago.

DB:AKP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 288.38 0.00 184.94
2019-09-30 281.68 0.00 173.21
2019-06-30 250.95 0.00 141.45
2019-03-31 269.07 0.00 166.74
2018-12-31 263.61 0.00 159.01
2018-09-30 255.27 0.00 149.01
2018-06-30 246.60 0.00 139.30
2018-03-31 263.77 0.00 163.05
2017-12-31 263.49 0.00 157.26
2017-09-30 253.29 0.00 152.71
2017-06-30 244.14 0.00 142.87
2017-03-31 230.03 0.00 138.62
2016-12-31 222.77 0.00 124.76
2016-09-30 214.54 0.00 120.30
2016-06-30 204.42 0.00 111.63
2016-03-31 195.37 0.00 115.84
2015-12-31 210.85 0.00 138.46
2015-09-30 199.75 0.00 130.48
2015-06-30 190.57 0.00 122.43
2015-03-31 181.82 0.00 112.30
2014-12-31 178.10 0.00 106.91
2014-09-30 169.70 0.00 91.77
2014-06-30 162.39 0.00 84.88
2014-03-31 156.57 0.00 82.16
2013-12-31 135.63 0.00 63.33
2013-09-30 128.21 8.40 64.06
2013-06-30 119.43 8.80 54.14
  • Anika Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Anika Therapeutics's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Anika Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Anika Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anika Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AKP Dividends

 What is Anika Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anika Therapeutics dividends.
If you bought €2,000 of Anika Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anika Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anika Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AKP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AKP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anika Therapeutics has not reported any payouts.
  • Unable to verify if Anika Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anika Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anika Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anika Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anika Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anika Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AKP Management

 What is the CEO of Anika Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cheryl Blanchard
COMPENSATION $167,377
AGE 55
TENURE AS CEO 0.2 years
CEO Bio

Dr. Cheryl R. Blanchard, Ph.D. serves as Interim Chief Executive Officer at Anika Therapeutics, Inc. since February 12, 2020. She is Director of Daré Bioscience, Inc since November 2019. She has been Member of Scientific Advisory Board at Bio2 Technologies, Inc. since July 2019 and served as its Director until July 2019. She has been a Director at Anika Therapeutics, Inc. in August, 2018. Shehad been the Chief Executive Officer at Microchips Biotech, Inc. since July 21, 2014 and served as President. Sheserved as the Chief Scientific Officer of Zimmer Holdings, Inc. (now known as Zimmer Biomet Holdings, Inc.) since December 13, 2005 and also served as its Senior Vice President. She served as Senior Vice President and Chief Scientific Officer of Zimmer, Inc. and General Manager of Zimmer Biologics. She is a medical device and biologics executive with leadership experience a medical device company focused on musculoskeletal products, including as the Senior Vice President, Corporate Chief Scientific Officer and General Manager of its Biologics Business. She served as an adjunct professor at the University of Texas Health Science Center, both in San Antonio, TX. During her 12 years with Zimmer, she operated in roles of increasing responsibility including global leadership of research and development, advanced technologies, clinical, quality and regulatory affairs, medical affairs, medical education, health economics, and reimbursement. She served as Senior Vice President of Research and Development at Zimmer Holdings Inc. since December 13, 2005. She served as Vice President of Corporate Research and Clinical Affairs at Zimmer Holdings Inc. since October 6, 2003. She had been an Independent Director of Neuronetics, Inc. since February 13, 2019 and served as director of Daré Bioscience, Inc since November 2019. She also served as Vice President of Research and Biologics at Zimmer Holdings, Inc. Shewas responsible for the research aspects of the Centerpulse Biologics group; the European Research functions in Winterthur, Switzerland; worldwide Clinical Affairs; and Zimmer and Centerpulse Spine research activities. Shejoined Zimmer in October of 2000 as Director of Research, having served in leadership roles at the Southwest Research Institute where he built and led the medical device practice, the University of Texas Health Science Center and the Oak Ridge National Laboratory. She has been a Director of Microchips Biotech, Inc. since July 21, 2014. She was Director of SeaSpine Holdings Corporation since July 2015 until May 30, 2019. In 2015, she was elected to the National Academy of Engineering, among the highest professional distinctions accorded to an engineer. Sheserved as a Director of ISTO Technologies, Inc. She holds a Bachelor of Science degree in Ceramic Engineering from Alfred University, New York and a Master’s of Science and Ph.D. in Materials Science and Engineering, both from the University of Texas (at Austin).

CEO Compensation
  • Insufficient data for Cheryl to compare compensation growth.
  • Cheryl's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Anika Therapeutics management team in years:

1.4
Average Tenure
55
Average Age
  • The average tenure for the Anika Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Cheryl Blanchard

TITLE
Interim CEO & Director
COMPENSATION
$167K
AGE
55
TENURE
0.2 yrs

Sylvia Cheung

TITLE
CFO, Treasurer & Secretary
COMPENSATION
$1M
AGE
44
TENURE
7 yrs

Tom Finnerty

TITLE
Executive Vice President of Human Resources
COMPENSATION
$759K
AGE
61
TENURE
2.5 yrs

Alexei Goraltchouk

TITLE
Vice President of Operations
TENURE
1.8 yrs

Charles Sherwood

TITLE
VP & Corporate Legal Counsel
TENURE
2.3 yrs

David Colleran

TITLE
Executive VP
AGE
47
TENURE
0.1 yrs

Stephen Goldy

TITLE
Vice President of U.S. Sales
TENURE
0.9 yrs

Jim Loerop

TITLE
Executive Vice President of Business Development & Strategic Planning
TENURE
0.8 yrs

Steve Garbacz

TITLE
VP of Finance & Corporate Controller
AGE
60
TENURE
0.9 yrs

Steven Cyr

TITLE
Vice President of Human Resources
TENURE
6.1 yrs
Board of Directors Tenure

Average tenure and age of the Anika Therapeutics board of directors in years:

3.6
Average Tenure
64.5
Average Age
  • The tenure for the Anika Therapeutics board of directors is about average.
Board of Directors

Joseph Bower

TITLE
Independent Chairman
COMPENSATION
$189K
AGE
80
TENURE
2.1 yrs

Cheryl Blanchard

TITLE
Interim CEO & Director
COMPENSATION
$167K
AGE
55
TENURE
1.7 yrs

Raymond Land

TITLE
Independent Director
COMPENSATION
$165K
AGE
74
TENURE
14.3 yrs

Jeff Thompson

TITLE
Independent Director
COMPENSATION
$157K
AGE
53
TENURE
9.3 yrs

Glenn Larsen

TITLE
Independent Director
COMPENSATION
$152K
AGE
64
TENURE
5.2 yrs

Sue Vogt

TITLE
Independent Director
COMPENSATION
$160K
AGE
65
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • Anika Therapeutics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Feb 20 Sell Raymond Land Individual 26. Feb 20 26. Feb 20 -2,700 €39.24 €-105,936
30. Aug 19 Sell Glenn Larsen Individual 28. Aug 19 28. Aug 19 -4,355 €51.61 €-224,783
22. Aug 19 Sell Joseph Bower Individual 20. Aug 19 20. Aug 19 -1,994 €50.11 €-99,914
12. Aug 19 Sell Jeffrey Thompson Individual 08. Aug 19 08. Aug 19 -4,843 €50.54 €-244,741
X
Management checks
We assess Anika Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anika Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AKP News

Simply Wall St News

AKP Company Info

Description

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Details
Name: Anika Therapeutics, Inc.
AKP
Exchange: DB
Founded: 1983
$365,474,507
14,168,080
Website: http://www.anikatherapeutics.com
Address: Anika Therapeutics, Inc.
32 Wiggins Avenue,
Bedford,
Massachusetts, 01730,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ANIK Common Stock Nasdaq Global Select US USD 03. May 1993
DB AKP Common Stock Deutsche Boerse AG DE EUR 03. May 1993
BRSE AKP Common Stock Berne Stock Exchange CH CHF 03. May 1993
Number of employees
Current staff
Staff numbers
154
Anika Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 20:34
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/10
Last earnings filing: 2020/03/06
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.